ScaleReady announces a G-Rex® Grant has been awarded to Dr. Eric Tran of the Earle A. Chiles Research Institute, a division of Providence Cancer Institute
ScaleReady has awarded a G-Rex Grant of $200,000 to Dr. Eric Tran of the Earle A. Chiles Research Institute, a division of Providence Cancer Institute. The grant will support process development and IND enabling studies for a novel KRAS-targeted TCR-T cell therapy.
Dr. Tran plans to optimize the manufacturing process by reducing duration and implementing fully-closed system G-Rex bioreactors. The project will utilize Bio-Techne's new GMP cytokines, designed for one-touch G-Rex close process manufacturing.
The G-Rex Grant Program is a $20M initiative by ScaleReady to advance cell and gene-modified cell therapy development and manufacturing. Recipients gain access to support from G-Rex Grant Partners, offering expertise in cGMP manufacturing, quality and regulatory affairs, and CGT business operations.
ScaleReady ha conferito un G-Rex Grant di 200.000 dollari a Dr. Eric Tran dell'Earle A. Chiles Research Institute, una divisione del Providence Cancer Institute. Il finanziamento supporterà lo sviluppo del processo e gli studi di abilitazione IND per una nuova terapia TCR-T mirata a KRAS.
Il Dr. Tran intende ottimizzare il processo di produzione riducendo la durata e implementando bioreattori G-Rex a sistema chiuso. Il progetto utilizzerà le nuove citochine GMP di Bio-Techne, progettate per una produzione a processo chiuso G-Rex con un solo tocco.
Il G-Rex Grant Program è un'iniziativa da 20 milioni di dollari promossa da ScaleReady per promuovere lo sviluppo e la produzione di terapie cellulari e di cellule modificate genicamente. I beneficiari avranno accesso al supporto dei Partner del G-Rex Grant, che offrono competenze nella produzione cGMP, nelle questioni di qualità e normative, e nelle operazioni commerciali CGT.
ScaleReady ha otorgado una Subvención G-Rex de 200,000 dólares al Dr. Eric Tran del Earle A. Chiles Research Institute, una división del Providence Cancer Institute. La subvención apoyará el desarrollo de procesos y estudios de habilitación para IND de una novedosa terapia celular TCR-T dirigida a KRAS.
El Dr. Tran planea optimizar el proceso de fabricación reduciendo la duración e implementando bioreactores G-Rex de sistema totalmente cerrado. El proyecto utilizará nuevas citoquinas GMP de Bio-Techne, diseñadas para la fabricación de procesos G-Rex con un solo toque.
El Programa de Subvenciones G-Rex es una iniciativa de 20 millones de dólares de ScaleReady para avanzar en el desarrollo y la fabricación de terapias celulares y modificadas genéticamente. Los beneficiarios obtienen acceso al apoyo de los Socios de Subvención G-Rex, que ofrecen experiencia en fabricación cGMP, asuntos de calidad y regulación, y operaciones comerciales CGT.
ScaleReady는 Providence Cancer Institute의 한 부서인 Earle A. Chiles Research Institute의 Dr. Eric Tran에게 200,000달러의 G-Rex Grant를 수여했습니다. 이 보조금은 새로운 KRAS를 목표로 하는 TCR-T 세포 요법의 프로세스 개발 및 IND 승인 연구를 지원할 것입니다.
Tran 박사는 제조 프로세스를 최적화하여 기간을 단축하고 완전 밀폐 시스템 G-Rex 생물 반응기를 구현할 계획입니다. 이 프로젝트는 Bio-Techne의 새로운 GMP 사이토카인을 사용하여 G-Rex 밀폐형 프로세스 제작을 위한 단일 터치 시스템을 적용합니다.
G-Rex Grant Program은 ScaleReady가 세포 및 유전자 수정 세포 요법의 개발 및 제조를 발전시키기 위해 마련한 2천만 달러 규모의 이니셔티브입니다. 수혜자는 cGMP 제조, 품질 및 규제 문제, 그리고 CGT 상업 운영에 대한 전문 지식을 제공하는 G-Rex Grant 파트너의 지원을 받을 수 있습니다.
ScaleReady a attribué une Subvention G-Rex de 200 000 dollars au Dr. Eric Tran de l'Earle A. Chiles Research Institute, une division du Providence Cancer Institute. Cette subvention soutiendra le développement de processus et des études de validation IND pour une nouvelle thérapie cellulaire TCR-T ciblant KRAS.
Le Dr Tran prévoit d'optimiser le processus de fabrication en réduisant sa durée et en mettant en œuvre des bioreacteurs G-Rex totalement fermés. Le projet utilisera les nouvelles cytokines GMP de Bio-Techne, conçues pour la fabrication à processus fermé G-Rex en un seul geste.
Le Programme de Subventions G-Rex est une initiative de 20 millions de dollars de ScaleReady pour faire progresser le développement et la fabrication de thérapies cellulaires et de cellules modifiées génétiquement. Les bénéficiaires auront accès à un soutien de la part des Partenaires de Subvention G-Rex, offrant leur expertise en fabrication cGMP, en affaires qualité et réglementaires, et en opérations commerciales CGT.
ScaleReady hat einen G-Rex Grant in Höhe von 200.000 Dollar an Dr. Eric Tran des Earle A. Chiles Research Institute, einer Abteilung des Providence Cancer Institute, vergeben. Der Zuschuss wird die Prozessentwicklung und IND-fähige Studien für eine neuartige KRAS-zielgerichtete TCR-T-Zelltherapie unterstützen.
Dr. Tran plant, den Herstellungsprozess zu optimieren, indem er die Dauer verkürzt und vollständig geschlossene G-Rex-Bioreaktoren implementiert. Das Projekt wird Bio-Techne's neue GMP-Zytochine nutzen, die für die G-Rex-Herstellung mit einem einzigen Touch konzipiert sind.
Das G-Rex Grant Program ist eine 20 Millionen Dollar umfassende Initiative von ScaleReady, um die Entwicklung und Herstellung von Zell- und genmodifizierten Zelltherapien voranzutreiben. Die Empfänger erhalten Zugang zu Unterstützung von G-Rex Grant-Partnern, die Expertise in cGMP-Herstellung, Qualitäts- und Regulierungsangelegenheiten sowie CGT-Geschäftsoperationen anbieten.
- ScaleReady awarded a $200,000 G-Rex Grant to support development of a novel KRAS-targeted TCR-T cell therapy
- The grant will help expedite an IND application for a Phase 1/1b clinical trial
- Implementation of fully-closed system G-Rex bioreactors and Bio-Techne's GMP cytokines to optimize manufacturing process
- None.
Insights
The G-Rex Grant awarded to Dr. Eric Tran represents a significant boost for the development of a novel KRAS-targeted TCR-T cell therapy. This
Key points to consider:
- The grant supports optimization of manufacturing processes, including reduced duration and implementation of fully-closed system G-Rex bioreactors.
- Utilization of Bio-Techne's new GMP cytokines, designed for one-touch G-Rex close process manufacturing, could enhance efficiency and scalability.
- The planned Phase 1/1b clinical trial targeting various solid tumors with KRAS mutations could have broad implications in oncology.
- This grant is part of a larger
$20 million initiative by ScaleReady, potentially catalyzing significant advancements in cell and gene therapy development.
While this news is positive for the research team and potentially for cancer patients, its immediate impact on Bio-Techne's stock (TECH) may be However, long-term investors should monitor the progress of this research, as successful outcomes could lead to increased demand for Bio-Techne's products in the expanding cell therapy market.
"We have utilized G-Rex devices for a long time for our adoptive cell therapy efforts. This G-Rex Grant will substantially defray the costs associated with bringing our next generation TCR-T cell therapy into the clinic and advance the state of our manufacturing," said Dr. Tran
"Dr. Tran has been contributing to the field of cell and gene therapy for nearly 15 years and we are grateful for the opportunity to award a G-Rex Grant to Dr. Tran and the Providence Cancer Institute.
As part of the G-Rex Grant, Dr. Tran plans to optimize their manufacturing process by reducing the process duration and implementing fully-closed system G-Rex bioreactors. Dr. Tran will make use of Bio-Techne's new GMP cytokines that have been right-sized for one-touch G-Rex close process manufacturing, setting the stage for simple and efficient scale out.
ScaleReady's G-Rex® Grant Program is a
About ScaleReady
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.
Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About CellReady LLC
CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time.
About Providence Cancer Institute of
Providence Cancer Institute of
View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-dr-eric-tran-of-the-earle-a-chiles-research-institute-a-division-of-providence-cancer-institute-302269620.html
SOURCE Bio-Techne Corporation
FAQ
What is the purpose of the G-Rex Grant awarded to Dr. Eric Tran?
How will the G-Rex Grant help optimize the manufacturing process for the TCR-T cell therapy?
What is the total value of ScaleReady's G-Rex Grant Program?
How does the G-Rex Grant relate to Bio-Techne (NASDAQ: TECH)?
